Conference call and webcast to begin at 8:30 AM ETAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.…
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit…
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…
Trial builds upon promising evidence of clinical activity of TTX-080 when combined cetuximab, presented at ASCO 2024SOUTH SAN FRANCISCO, Calif.,…
Accomplished Finance and Commercial Leader Brings Extensive Life Sciences ExpertiseCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc.…
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling…
Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary…
BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome…